Product logins

Find logins to all Clarivate products below.


Dr. Srikanth Rajagopal

Managing Partner and Vice President, Commercial Consulting Services

Doc is an experienced management consultant, client partner and practice leader, with close to 20 years of experience selling, leading & delivering a range of product and portfolio strategy, transaction advisory, evidence generation, pricing and market access, commercial strategy and transformation, and business innovation engagements for biopharmaceutical industry clients and their investors across the US, Europe, Asia-Pacific and Japan.​

He believes in a structured, collaborative, expertise-based approach to problem-solving and solution development. Doc partners with colleagues across Clarivate to harness our deep expertise in global healthcare systems, policy, drug development and approval, therapy areas and indications, business development and licensing, pricing and reimbursement systems and processes, customer engagement models and data and advanced analytics to deliver exceptional, impactful outcomes for our clients.​

He previously led Clarivate Europe, Asia-Pacific and Japan Commercial Consulting business, and has held positions of increasing responsibility at global consulting firms such as Guidehouse, IQVIA and Strategic Decisions Group (SDG).

By way of academic qualifications, Doc holds an MBA from the Indian Institute of Management, Ahmedabad and an MBBS (MD equivalent) from the University of Mumbai.


arrow_forward
Get in touch with Srikanth

Latest news

News August 6, 2026
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle London, U.K. — August 6, 2026— Clarivate…

News August 5, 2026
Clarivate Companies to Watch Report Spotlights Seven Innovators Shaping the Next Generation of Obesity Therapies

New report examines novel mechanisms and emerging approaches advancing obesity treatment beyond today’s GLP-1 therapies London, U.K., August 5, 2026 — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative…

News July 29, 2026
Clarivate Appoints Michael Easton as Chief Financial Officer

Experienced Clarivate leader brings more than 25 years of financial and operational expertise ​LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.